An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
Status:
Completed
Trial end date:
2018-03-21
Target enrollment:
Participant gender:
Summary
This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression
potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve
hours for two weeks, in pediatric patients 9 to less than 12 years of age with acne vulgaris.
Adrenal suppression effects and systemic safety are an important safety concern. The current
study is designed to investigate these potential concerns under maximal use conditions.